Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs

Frontiers in Oncology
Chia-Hao ChangChong-Jen Yu

Abstract

Through activation of adrenergic receptors, chronic stress can trigger the secretion of neurotransmitters and hormones that enhance tumor growth, increase angiogenesis, and promote drug resistance. This study aimed to evaluate the effect of β-blockers in patients receiving first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for lung adenocarcinoma. This retrospective cohort study enrolled patients with advanced lung adenocarcinoma under first-line EGFR-TKIs between 2011 and 2014 in the National Health Insurance Research Database of Taiwan. The effects of β-blockers use, defined as ≥60 defined daily doses within 180 days before initiation of EGFR-TKI therapy, on the 2-year time-to-discontinuation (TTD) of EGFR-TKIs and 4-year overall survival (OS) were investigated using Cox regression analyses with inverse propensity score weighting and sensitivity analysis in subgroup with either hypertension or ischemic heart diseases. Among 4988 enrolled patients, 552 (11.1%) were in the β-blocker group. Patients in the β-blocker group were more likely to be older than 75 and had diabetes mellitus and cardiovascular comorbidities. In Cox regression analysis, β-blocker usage was associated with a longer TTD (haz...Continue Reading

References

Jan 14, 2004·Chest·C Martin TammemagiPaul Kvale
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Oct 1, 2011·Cancer Prevention Research·Hussein A N Al-WadeiHildegard M Schuller
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul W SperdutoMinesh Mehta
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jan 10, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H M WangD R Gomez
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa MartinVickie E Baracos
Jan 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yuankai ShiPan-Chyr Yang
Feb 1, 2014·Journal of Clinical Anesthesia·Juan P CataVijaya Gottumukkala
Jul 2, 2014·Nature Reviews. Clinical Oncology·D Ross CamidgeLecia V Sequist
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Jan 30, 2015·Frontiers in Oncology·Peder Rustøen BraadlandKristin Austlid Taskén
Jun 20, 2015·International Journal of Cancer. Journal International Du Cancer·Jheelam BanerjeeHildegard M Schuller
Oct 31, 2015·Clinical Breast Cancer·W Kurtis ChildersPramil Cheriyath
Nov 26, 2015·Journal of Cancer Research and Clinical Oncology·Roberta Colucci, Silvia Moretti
Nov 10, 2017·Science Translational Medicine·Monique B NilssonJohn V Heymach
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Nov 22, 2019·The New England Journal of Medicine·Suresh S RamalingamUNKNOWN FLAURA Investigators

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Software Mentioned

R for
R

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
Kai LiuXiaoping Chen
JAMA : the Journal of the American Medical Association
John Cruickshank
Reviews in Cardiovascular Medicine
Norman E Lepor
JAMA : the Journal of the American Medical Association
Todd Stern, Adam S Cifu
© 2021 Meta ULC. All rights reserved